ArticlePloS one2026
Multi-task adaptive deep sparse canonical correlation analysis for multi-omics cancer survival prediction.
Article in PloS one, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Integrating high-dimensional multi-omics data is essential for uncovering the coordinated molecular mechanisms underlying cancer progression and improving survival prediction. DNA methylation and mRNA expression represent two tightly coupled regulatory layers; however, many existing approaches either model them independently or rely on linear assumptions that fail to capture the nonlinear cross-omics structure. Here, we propose MT-ADSCCA, a multitask adaptive deep sparse canonical correlation analysis framework that jointly learns correlated latent representations, selects interpretable multi-omics biomarkers, and supports downstream survival modeling. MT-ADSCCA embeds sparse CCA into a nonlinear encoder architecture and uses uncertainty-guided adaptive weighting to stabilize multi-objective training. The selected features were subsequently modeled using a BiLSTM-Cox survival network with genes ordered by chromosomal coordinates to capture local genomic dependencies. We evaluated MT-ADSCCA using event-stratified nested 10-fold cross-validation across three TCGA cohorts: breast invasive carcinoma (BRCA), glioma (GBMLGG), and pan-kidney carcinoma (KIPAN), including 485, 563, and 652 matched multi-omics samples, respectively. MT-ADSCCA achieved the highest concordance indices across all cohorts, outperforming six feature-selection baselines (DA, WGCNA, lmQCM, CCA, OSCCA, DeepCorrSurv) and four survival-model baselines (LASSO-Cox, RSF, MTLSA, DeepSurv). Kaplan-Meier analyses further confirmed a clear separation between the predicted high- and low-risk groups. The selected canonical features were enriched in biologically coherent functional categories, supporting the interpretability of the learned patterns. Together, these results demonstrate that MT-ADSCCA provides a robust and interpretable framework for multi-omics integration and cancer prognosis prediction.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.